Latus Bio
PrivateLast Round
Series A
May 4, 2026
Total Funding Raised
$194M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Latus Bio is a biotechnology company that develops precision gene therapies for central nervous system and peripheral diseases using proprietary AAV capsid engineering and computational discovery platforms.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Latus Bio Comparables
Compare Latus Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Capsida Biotherapeutics | 84% | |
| Capsigen | 84% | |
| Apertura Gene Therapy | 84% |
Latus Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 4, 2026 | ||||
| Series A | May 2, 2024 |
Latus Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Helen's Pink Sky Foundation | Series A |
| Benjamin Franklin Technology Partners | Series A |
| DCVC Bio | Series A |
| Gaingels | Series A |
| Korea Development Bank | Series A |
| BioAdvance Capital | Series A |
| 8VC | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 4, 2026
$97M round led by 8VC and DCVC Bio.
- Nov 3, 2025
Launched an AI/ML strategy for AAV gene therapy and added two scientific advisors.
Recent news
Latest coverage and updates
- is_developingOct 13, 2026
Latus Bio, Inc. is developing engineered AAV capsids designed to improve the delivery and targeting of gene therapies for central nervous system and peripheral diseases.
- attends_eventOct 13, 2026
Latus Bio, Inc.'s senior research scientist Katherine L. Villa is scheduled to present preclinical kidney gene-therapy findings at the American Society of Nephrology's Kidney Week 2026 conference in Colorado, which runs Oct 21st-25th '26.
- hiresSep 10, 2026
Latus Bio, Inc. hired Donald Hayden as Chairman of the Board on Sep 9th '26.
- hiresSep 9, 2026
Latus Bio, Inc. hired Michael MacLean as Independent Director and Chair of the Audit Committee on Sep 9th '26.
- hiresSep 9, 2026
Latus Bio, Inc. hired Don as Chairman of the Latus Board of Directors on Sep 9th '26.
Latus Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Latus Bio's valuation, stock price, and market status.
Is Latus Bio a public or private company?
Latus Bio is a private company.
What is the current stock price of Latus Bio?
Latus Bio is a private company, so its shares have no public market price. Caplight tracks Latus Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Latus Bio worth (valuation)?
Valuation information for Latus Bio is not publicly available.
Can I buy Latus Bio stock?
Latus Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Latus Bio's last funding round?
Latus Bio's most recent funding round was Series A on May 4, 2026.
Who are the main investors in Latus Bio?
Key investors in Latus Bio include DCVC Bio, 8VC, DCVC (Data Collective).
Will Latus Bio IPO soon?
No public IPO plans have been announced for Latus Bio.
How can I track Latus Bio secondary market activity?
Caplight tracks bids, offers, and trades in Latus Bio's shares on secondary markets.